Novo Nordisk (NVO) stock took a hit this week, after a Super Bowl ad highlighted a growing challenge to the company’s ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Long-Term Pick. In this article, we will summarize ...

Novo Nordisk A/S shares are on track for their worst week this year, after a Super Bowl advertisement touting copycat ...

Telehealth company Hims & Hers stirred up controversy by debuting a 2025 Super Bowl ad touting the benefits of its ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Bank of America Securities analyst Sachin Jain maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

Kingsview Wealth Management LLC reduced its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) by 76.9% during the 4th quarter, according to the company in its most recent 13F filing with ...

Shortly after Hims & Hers aired its controversial Super Bowl ad promoting its compounded GLP-1 offerings, Novo Nordisk has ...

LONDON (Reuters) – The Novo Nordisk Foundation does not plan to step in to prop ... Rob Nabors, who leads the Gates ...

Sales of Novo Nordisk’s obesity drugs, such as Wegovy, rose by more than 50 per cent last year, helping send shares in Europe’s most valuable listed company almost 5 per cent higher.  The Danish ...

That growth was driven primarily by demand from the North America and Europe, Middle East and Africa regions. Novo Nordisk forecast slower sales growth for 2025 of between 16% to 24% at constant ...

Novo Nordisk has been manufacturing some active ... company did ship ingredients for its diabetes drug Ozempic into North America, where the final manufacturing is done. “I think we are also ...